Novo Nordisk’s Semaglutide Hits Mark in Type 2 Diabetes Trial

Semaglutide has already been approved by the U.S. Food and Drug Administration (FDA)under the brand name Ozempic as a type 2 diabetes treatment. Ozempic was approved by the FDA in December 2017 and was launched for commercialization in the U.S. in February.

Article CTA